We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
News

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
News

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Resverlogix Corp. has announced that the first patient has been randomized and dosing has commenced in the Phase 3 clinical trial 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM).

The primary outcome measure will assess the effect of apabetalone on time to first occurrence of Major Adverse Cardiovascular Events (MACE) in high-risk type 2 DM patients with CAD.

In the primary outcome measure, MACE is narrowly defined as a single composite endpoint of cardiovascular death, or non-fatal myocardial infarction (MI), or stroke. All subjects will remain on a high-dose statin therapy (atorvastatin or rosuvastatin), with the experimental group receiving 200 mg/day of apabetalone in the form of 100 mg capsules twice daily. Additional trial details and updates can be found at: www.clinicaltrials.gov and/or www.clinicaltrialsregister.eu/.

Dr. Michael Sweeney, senior vice president of clinical development stated, "We are pleased to announce that dosing has commenced in BETonMACE only two weeks after of the opening of our first sites. Every team member has worked exceptionally hard to expedite the process with rigorous attention to detail."

Advertisement